ImmunityBio (IBRX) and nCartes said Thursday they are collaborating to automate and streamline the data fulfillment process for clinical trials.
The collaboration will help expedite the process and make it less expensive for ImmunityBio's trial investigators, the companies said.
ImmunityBio shares were up about 2% in recent trading.
Price: 4.98, Change: +0.11, Percent Change: +2.15
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments